Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.90 · Revenue $0.00 · 11 analysts
Est. EPS $-0.89 · Revenue $0.00 · 11 analysts
Est. EPS $-3.59 · Revenue $995727.00 · 13 analysts
Est. EPS $-0.86 · Revenue $2.99M · 4 analysts
EPS $-1.05 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-446.2M | -40.6% | -47.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-405.1M | -37.4% | +9.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 2.1% | -45.2% | +26.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 22.25x | +42.6% | -39.7% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.2B | +71.7% | -8.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.47 vs -3.50 | +0.9% | -1.08 vs -0.75 | -44.2% |
| Revenue Surprise | $0 vs $692308 | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Rhodes Jason P | director | Common Stock | D | 1,359,674 | $25.00 |
| Aug 14, 2026 | Rhodes Jason P | director | Common Stock | D | 478,377 | $25.00 |
| Aug 14, 2026 | Rhodes Jason P | director | Common Stock | D | 322,465 | $25.00 |
| Aug 13, 2026 | Rhodes Jason P | director | Common Stock | D | 268,354 | $26.20 |
| Aug 13, 2026 | Rhodes Jason P | director | Common Stock | D | 94,415 | $26.20 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
John G. Cox | Chief Executive Officer, President & Director | USD 1,138,975 | Male | 1963 | Active |
Johanna Friedl-Naderer | Chief Commercial Officer | USD 842,754 | Female | 1968 | Active |
Douglas Kerr | Chief Medical Officer | USD 748,065 | — | 1967 | Active |
Oxana Beskrovnaya | Chief Innovation Officer | USD 740,475 | — | 1961 | Active |
Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | USD 726,892 | Male | 1968 | Active |
Alessandro Martuscelli | Chief Legal Officer | — | Male | — | Active |
James Bilotta | Chief Digital & Information Officer | — | Male | — | Active |
Debra Feldman | Chief Regulatory Affairs Officer | — | Female | 1971 | Active |
Lucia Celona | Chief Human Resource Officer | — | Female | 1966 | Active |
Rajesh Manchanda | Chief Technical Officer | — | — | 1967 | Active |
Daniel Wilson | Senior Vice President & Head of Legal | — | Male | 1972 | Active |
Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations | — | — | — | Active |
ADAR1 Capital Management LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 42,821 shares of the company's stock, valued at approximately $951,000. Other institutional investors
Deutsche Bank AG purchased a new position in Dyne Therapeutics, Inc. (NASDAQ: DYN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 242,392 shares of the company's stock, valued at approximately $5,384,000. Deutsche Bank AG owned approximately
WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -
- Company's third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease -
